open access

Vol 51, No 2 (2020)
ORIGINAL RESEARCH ARTICLE
Submitted: 2019-11-27
Published online: 2020-06-01
Get Citation

Prognostic impact of Epstein-Barr virus serostatus in patients with nonmalignant hematological disorders undergoing allogeneic hematopoietic cell transplantation: the study of Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation

Jan Styczynski1, Gloria Tridello2, Lidia Gil3, Per Ljungman4, Malgorzata Mikulska5, Steffie van der Werf6, Nina Simone Knelange6, Diana Averbuch7, Gerard Socié8, Hendrik Veelken9, Jean-Hugues Dalle10, Mahmoud Aljurf11, Alphan Kupesiz12, Yves Bertrand13, Abdelghani Tbakhi14, Boris Afanasyev15, Bruno Lioure16, Hélène Labussière-Wallet17, Xavier Poiré18, Johan Maertens19, Eefke Petersen2021, Patrice Chevallier22, Noel Milpied23, John A. Snowden24, Ibrahim Yakoub-Agha, Jan Cornelissen25, Nicolaas Schaap21, Carlo Dufour26, Regis Peffault de Latour8, Arjan Lankester9, Simone Cesaro2
DOI: 10.2478/ahp-2020-0015
·
Acta Haematol Pol 2020;51(2):73-80.
Affiliations
  1. Department of Pediatric Hematology and Oncology, Jurasz University Hospital, Collegium Medicum UMK Toruń, Bydgoszcz, Poland
  2. Pediatric Hematology Oncology, Ospedale Donna Bambino, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
  3. Department of Hematology, Medical University of Białystok, Poland
  4. Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital, and Division of Hematology, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden
  5. Division of Infectious Diseases, Department of Health Sciences, University of Genova, Ospedale Policlinco San Martino, Genova, Italy
  6. EBMT Data Office, Array, Leiden, The Netherlands
  7. Hadassah University Hospital, Array, Jerusalem, Israel
  8. Hopital St. Louis, Array, Paris, France
  9. Leiden University Hospital, Array, Leiden, The Netherlands
  10. Hôpital Robert Debre, Array, Paris, France
  11. King Faisal Specialist Hospital & Research Centre, Array, Riyadh, Saudi Arabia
  12. Akdeniz University Medical School, Array, Antalya, Turkey
  13. Institut d'Hematologie et d'Oncologie Pediatrique, Array, Lyon, France
  14. King Hussein Cancer Centre, Array, Amman, Jordan
  15. First State Pavlov Medical University of St. Petersburg, Array, St. Petersburg
  16. Techniciens d'Etude Clinique suivi de patients greffes, Array, Strasbourg, France
  17. Centre Hospitalier Lyon Sud, Array, Lyon, France
  18. Cliniques Universitaires St. Luc, Array, Brussels, Belgium
  19. University Hospital Gasthuisberg, Array, Leuven, Belgium
  20. University Medical Centre, Array, Utrecht, The Netherlands
  21. Radboud University Medical Centre, Array, Nijmegen, The Netherlands
  22. CHU Nantes, Array, Nantes, France
  23. CHU Bordeaux, Array, Pessac, France
  24. Sheffield Teaching Hospitals NHS Trust, Array, Sheffield
  25. Erasmus MC Cancer Institute, Array, Rotterdan, The Netherlands
  26. Instituto Giannina Gaslini, Genova, Italy

open access

Vol 51, No 2 (2020)
ORIGINAL RESEARCH ARTICLE
Submitted: 2019-11-27
Published online: 2020-06-01

Abstract

Background

In patients with acute leukemia, lymphoma and chronic malignancies, donor and/or recipient Epstein-Barr virus (EBV) seropositive status increases the risk of development of chronic graft-versus-host disease (cGVHD) after allo-hematopoietic cell transplantation (allo-HCT), while it has no influence on other transplant outcomes. No data are available on the impact of EBV serostatus on transplant outcomes in patients with nonmalignant hematological disorders.

Objective

We analyzed the influence of the recipient's (R) and donor's (D) EBV serostatus on transplant outcomes (overall survival (OS); relapse-free survival (RFS); relapse incidence (RI); nonrelapse mortality (NRM); acute graft-versus-host disease (aGVHD); cGVHD) in patients with nonmalignant hematological disorders undergoing allo-HCT.

Patients and Methods

A total of 2,355 allo-HCTs performed between 1997 and 2016 for acquired bone marrow failure or hemoglobinopathies were included in this retrospective Registry megafile Infectious Diseases Working Party of the European Society of Blood and Marrow Transplantation (IDWP-EBMT) study.

Results

Array

Conclusions

Allo-HCT from EBV-seropositive versus EBV-seronegative donors are at 31% higher risk of cGVHD in patients with nonmalignant hematological disorders undergoing allo-HCT; however this difference is nonsignificant in multivariate analysis.

Abstract

Background

In patients with acute leukemia, lymphoma and chronic malignancies, donor and/or recipient Epstein-Barr virus (EBV) seropositive status increases the risk of development of chronic graft-versus-host disease (cGVHD) after allo-hematopoietic cell transplantation (allo-HCT), while it has no influence on other transplant outcomes. No data are available on the impact of EBV serostatus on transplant outcomes in patients with nonmalignant hematological disorders.

Objective

We analyzed the influence of the recipient's (R) and donor's (D) EBV serostatus on transplant outcomes (overall survival (OS); relapse-free survival (RFS); relapse incidence (RI); nonrelapse mortality (NRM); acute graft-versus-host disease (aGVHD); cGVHD) in patients with nonmalignant hematological disorders undergoing allo-HCT.

Patients and Methods

A total of 2,355 allo-HCTs performed between 1997 and 2016 for acquired bone marrow failure or hemoglobinopathies were included in this retrospective Registry megafile Infectious Diseases Working Party of the European Society of Blood and Marrow Transplantation (IDWP-EBMT) study.

Results

Array

Conclusions

Allo-HCT from EBV-seropositive versus EBV-seronegative donors are at 31% higher risk of cGVHD in patients with nonmalignant hematological disorders undergoing allo-HCT; however this difference is nonsignificant in multivariate analysis.

Get Citation

Keywords

hematopoietic cell transplant; graft-versus-host disease; Epstein-Barr virus; overall survival

About this article
Title

Prognostic impact of Epstein-Barr virus serostatus in patients with nonmalignant hematological disorders undergoing allogeneic hematopoietic cell transplantation: the study of Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation

Journal

Acta Haematologica Polonica

Issue

Vol 51, No 2 (2020)

Pages

73-80

Published online

2020-06-01

Page views

134

Article views/downloads

141

DOI

10.2478/ahp-2020-0015

Bibliographic record

Acta Haematol Pol 2020;51(2):73-80.

Keywords

hematopoietic cell transplant
graft-versus-host disease
Epstein-Barr virus
overall survival

Authors

Jan Styczynski
Gloria Tridello
Lidia Gil
Per Ljungman
Malgorzata Mikulska
Steffie van der Werf
Nina Simone Knelange
Diana Averbuch
Gerard Socié
Hendrik Veelken
Jean-Hugues Dalle
Mahmoud Aljurf
Alphan Kupesiz
Yves Bertrand
Abdelghani Tbakhi
Boris Afanasyev
Bruno Lioure
Hélène Labussière-Wallet
Xavier Poiré
Johan Maertens
Eefke Petersen
Patrice Chevallier
Noel Milpied
John A. Snowden
Ibrahim Yakoub-Agha
Jan Cornelissen
Nicolaas Schaap
Carlo Dufour
Regis Peffault de Latour
Arjan Lankester
Simone Cesaro

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl